<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9465">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05697224</url>
  </required_header>
  <id_info>
    <org_study_id>soh-med-22-11-12</org_study_id>
    <nct_id>NCT05697224</nct_id>
  </id_info>
  <brief_title>Aschistosoma Haematobiumspecific microRNAas a Tumor Marker for Early Diagnosis and Prognosis of Bilharzial Bladder Cancer in Eygpt</brief_title>
  <official_title>Role of Aschistosoma Haematobiumspecific microRNAas Atumor Marker for Early Diagnosis and Prognosis of Bilharzial Bladder Cancer in Eygpt</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      miRNAs have been detected in different bodily fluids, which suggests significant potential,&#xD;
      such as their use as biomarkers in diagnostics and prognostics. Sha-mir-71a was abundantly&#xD;
      found in the urine of patients with bladder cancer as compared to benign bladder cystitis&#xD;
      associated with schistosomiasis . Additionally, this miRNA was more highly detected in urine&#xD;
      samples from patients with bilharzial bladder cancer than bladder cancer not associated with&#xD;
      bilharziasis (schistosomiasis), suggesting its specificity in the identification of bladder&#xD;
      cancer associated with infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2023</start_date>
  <completion_date type="Anticipated">May 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>use micro RNAas adiagnostic test for early diagnosis of shistosomal bladder cancer</measure>
    <time_frame>one year</time_frame>
    <description>Sha-mir-71a could be a biomarker with diagnostic and prognostic value</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>chronicurinary schistosomiasis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>bladder cancer diseased patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>urinary micro RNA detection</intervention_name>
    <description>Urinary Sha-miR-71a gene expression analysis Total RNA extraction and purification Sha-miR_71a gene expression analysis MAPK-3 gene expression analysis</description>
    <arm_group_label>bladder cancer diseased patients</arm_group_label>
    <arm_group_label>chronicurinary schistosomiasis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  urinary symptoms (hematuria, urinary retention, dysuriaâ€¦ etc.), who were planned to&#xD;
             undergo cystoscopy for suspicion of bladder cancer (BC) or benign bilharzial cystitis&#xD;
             (Bil), will be selected.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  : In bladder cancer group Patients who have received chemotherapy, or with previously&#xD;
             diagnosed other malignancy within the past 5 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>esraa o ali, assistant lecturer</last_name>
    <phone>01142171590</phone>
    <email>esraa.ismail@med.sohag.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>hanaa a hady, professor</last_name>
  </overall_contact_backup>
  <reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum In: CA Cancer J Clin. 2020 Jul;70(4):313.</citation>
    <PMID>30207593</PMID>
  </reference>
  <reference>
    <citation>Eissa S, Matboli M, Essawy NO, Kotb YM. Integrative functional genetic-epigenetic approach for selecting genes as urine biomarkers for bladder cancer diagnosis. Tumour Biol. 2015 Dec;36(12):9545-52. doi: 10.1007/s13277-015-3722-6. Epub 2015 Jul 3.</citation>
    <PMID>26138586</PMID>
  </reference>
  <reference>
    <citation>Abd El-Aal AA, Bayoumy IR, Basyoni MM, Abd El-Aal AA, Emran AM, Abd El-Tawab MS, Badawi MA, Zalat RM, Diab TM. Genomic instability in complicated and uncomplicated Egyptian schistosomiasis haematobium patients. Mol Cytogenet. 2015 Jan 22;8(1):1. doi: 10.1186/s13039-014-0104-5. eCollection 2015.</citation>
    <PMID>25628757</PMID>
  </reference>
  <reference>
    <citation>Chen L, Yuan L, Wang G, Cao R, Peng J, Shu B, Qian G, Wang X, Xiao Y. Identification and bioinformatics analysis of miRNAs associated with human muscle invasive bladder cancer. Mol Med Rep. 2017 Dec;16(6):8709-8720. doi: 10.3892/mmr.2017.7726. Epub 2017 Oct 4.</citation>
    <PMID>28990088</PMID>
  </reference>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 15, 2023</study_first_submitted>
  <study_first_submitted_qc>January 15, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2023</study_first_posted>
  <last_update_submitted>January 15, 2023</last_update_submitted>
  <last_update_submitted_qc>January 15, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Esraa Omar Ali</investigator_full_name>
    <investigator_title>assistant lecturar at parasitology department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

